参考文献/References:
［1］ Ezhilarasan D， Sokal E， Najimi M. Hepatic fibrosis： it is time to go with hepatic stellate cell- specific therapeutic targets［J］. Hepato- biliary Pancreat Dis Int， 2018， 17： 192- 197.
［2］ Behr J， Prasse A， Kreuter M， et al. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis（RELIEF）：a double- blind，randomised， placebo- controlled， phase 2b trial［J］. Lancet Respir Med， 2021， 9： 476- 486.
［3］ Sharawy MH，Serrya MS. Pirfenidone attenuates gentamicin- induced acute kidney injury by inhibiting inflammasome- dependent NLRP3 pathway in rats［J］. Life Sci， 2020， 260： 118454.
［4］ Xi Y，Li Y，Xu P，et al. The anti- fibrotic drug pirfenidone inhibits liver fibrosis by targeting the small oxidoreductase glutaredoxin- 1［J］. Sci Adv， 2021， 7： eabg9241.
［5］ Lv Q， Wang J， Xu C， et al. Pirfenidone alleviates pulmonary fibrosis in vitro and in vivo through regulating Wnt/GSK- 3β/β- catenin and TGF- β1/Smad2/3 signaling pathways［J］. Mol Med， 2020， 26： 49.
［6］ Spagnolo P， Cottin V. Genetics of idiopathic pulmonary fibrosis： from mechanistic pathways to personalised medicine［J］. J Med Genet， 2017， 54： 93- 99.
［7］ Guo J， Yang Z， Jia Q， et al. Pirfenidone inhibits epithelial- mesenchymal transition and pulmonary fibrosis in the rat silicosis model［J］. Toxicol Lett， 2019， 300： 59- 66.
［8］ Al- Kuraishy HM， Batiha GE， Faidah H， et al. Pirfenidone and post- covid- 19 pulmonary fibrosis： invoked again for realistic goals［J］. Inflammopharmacology， 2022， 30： 2017- 2026.
［9］ Tsuchida T， Friedman SL. Mechanisms of hepatic stellate cell activation［J］. Nat Rev Gastroenterol Hepatol， 2017， 14： 397- 411.
［10］ Bansal MB， Chamroonkul N. Correction to： antifibrotics in liver disease： are we getting closer to clinical use?［J］. Hepatol Int， 2019， 13： 40- 41.
［11］ Salah MM，Ashour AA，Abdelghany TM，et al. Pirfenidone alleviates concanavalin A- induced liver fibrosis in mice［J］. Life Sci， 2019， 239： 116982.
［12］ Armendáriz- Borunda J， Islas- Carbajal MC， Meza- Garcia E， et al. A pilot study in patients with established advanced liver fibrosis using pirfenidone［J］. Gut， 2006， 55： 1663- 1665.
［13］ Flores- Contreras L，Sandoval- Rodriguez AS，Mena- Enriquez MG，et al. Treatment with pirfenidone for two years decreases fibrosis， cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C［J］. BMC Gastroenterol， 2014， 14： 131.
［14］ Poo JL，Torre A，Aguilar- Ramirez JR，et al. Benefits of prolonged- release pirfenidone plus standard of care treatment in patients with advanced liver fibrosis： PROMETEO study［J］. Hepatol Int， 2020， 14： 817- 827.
［15］ Kong D， Zhang Z， Chen L， et al. Curcumin blunts epithelial- mesenchymal transition of hepatocytes to alleviate hepatic fibrosis through regulating oxidative stress and autophagy［J］. Redox Biol， 2020， 36： 101600.
［16］ Friedman SL. Hepatic stellate cells： protean， multifunctional， and enigmatic cells of the liver［J］. Physiol Rev， 2008， 88： 125- 172.
［17］ Yu F， Guo Y， Chen B， et al. LincRNA- p21 inhibits the Wnt/β- catenin pathway in activated hepatic stellate cells via sponging microRNA- 17- 5p［J］. Cell Physiol Biochem， 2017， 41： 1970- 1980.
［18］ Ruwanpura SM， Thomas BJ， Bardin PG. Pirfenidone： molecular mechanisms and potential clinical applications in lung disease［J］. Am J Respir Cell Mol Biol， 2020， 62： 413- 422.
［19］ Hernandez- Gea V，Ghiassi- Nejad Z，Rozenfeld R，et al. Auto-phagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues［J］. Gastroenterology， 2012， 142： 938- 946.
［20］ Liu N， Feng J， Lu X， et al. Isorhamnetin inhibits liver fibrosis by reducing autophagy and inhibiting extracellular matrix formation via the TGF- β 1/Smad3 and TGF- β 1/p38 MAPK pathways［J］. Mediators Inflamm， 2019， 2019： 6175091.
［21］ Gao J，Wei B，De Assuncao TM，et al. Hepatic stellate cell autophagy inhibits extracellular vesicle release to attenuate liver fibrosis［J］. J Hepatol， 2020， 73： 1144- 1154.
［22］ Zheng Y，Zhao T，Wang J，et al. Curcumol alleviates liver fibrosis through inducing autophagy and ferroptosis in hepatic stellate cells［J］. FASEB J， 2022， 36： e22665.
［23］ Ferro F，Servais S，Besson P，et al. Autophagy and mitophagy in cancer metabolic remodelling［J］. Semin Cell Dev Biol， 2020， 98： 129- 138.
［24］ Springer MZ， Poole LP， Drake LE， et al. BNIP3- dependent mitophagy promotes cytosolic localization of LC3B and metabolic homeostasis in the liver［J］. Autophagy， 2021， 17： 3530- 3546.
［25］ Zhang XW，Zhou JC，Peng D，et al. Disrupting the TRIB3- SQSTM1 interaction reduces liver fibrosis by restoring autophagy and suppressing exosome- mediated HSC activation［J］. Autophagy， 2020， 16： 782- 796.
［26］ Thoen LF，Guimaraes EL，Dolle L，et al. A role for autophagy during hepatic stellate cell activation［J］. J Hepatol， 2011， 55： 1353- 1360.
［27］ Zou WJ，Huang Z，Jiang TP，et al. Pirfenidone inhibits proliferation and promotes apoptosis of hepatocellular carcinoma cells by inhibiting the Wnt/β- catenin signaling pathway［J］. Med Sci Monit， 2017， 23： 6107- 6113.
相似文献/References:
[1]陈志伟,韩世松,安泳橙,等.维生素A修饰的纳米载体靶向肝星状细胞沉默TLR4基因并抑制其激活的体外实验研究[J].介入放射学杂志,2020,29(10):1008.
CHEN Zhiwei,HAN Shisong,AN Yongcheng,et al.Vitamin A- modified nanocarrier for targeted TLR4 siRNA delivery to hepatic stellate cells for anti-fibrotic treatment： an experimental study in vitro[J].journal interventional radiology,2020,29(07):1008.